IP Library Granted Patent US 7,282,204
Granted Patent B2
US 7,282,204 · App. 10/797,157 · Granted Oct 16, 2007

Uses of IL-23 agonists and antagonists; related reagents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,282,204
App. No.
10/797,157
Granted
Oct 16, 2007
Kind
B2
Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.

Claims (35)

1. A method of inhibiting tumor growth comprising contacting a tumor cell with an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide comprising residues 1-168 of SEQ ID NO:2.

2. The method of claim 1 , wherein the tumor cell expresses IL-23.

3. The method of claim 1 , wherein the binding composition comprises:

a) a polyclonal antibody;

b) a monoclonal antibody;

c) a humanized antibody, or a fragment thereof; or

d) an Fab, Fv, or F(ab′) 2 fragment.

4. The method of claim 1 , wherein the tumor cell is:

a) a colon cancer cell;

b) an ovarian cancer cell;

c) a breast cancer cell; or

d) a melanoma cell.

5. A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide comprising residues 1-168 of SEQ ID NO:2.

6. The method of claim 5 , wherein the binding composition inhibits:

a) growth of the cancer or tumor;

b) cachexia;

c) anorexia; or

d) angiogenesis.

7. The method of claim 5 , wherein the binding composition comprises:

a) a polyclonal antibody;

b) a monoclonal antibody;

c) a humanized antibody, or a fragment thereof; or

d) an Fab, Fv, or F(ab′) 2 fragment.

8. The method of claim 5 , wherein the cancer or tumor is of the:

a) gastrointestinal tract;

b) respiratory tract;

c) reproductive system; or

d) endocrine system.

9. The method of claim 5 , wherein the cancer or tumor is:

a) colon cancer;

b) ovarian cancer;

c) a melanoma; or

d) breast cancer.

10. A method of inhibiting tumor growth comprising contacting a tumor cell with an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide comprising the sequence of SEQ ID NO: 2.

11. A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide comprising the sequence of SEQ ID NO: 2.

Assignments (3)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2004
From: OFT, MARTIN; MCCLANAHAN, TERRILL K.
To: SCHERING CORPORATION
Reel/Frame 014813/0574 →